Resource: Antithrombotic Therapy in Patients with COVID-19
Source: National Institutes of Health (NIH)
Synopsis: The above reference is a summary of recommendations from the NIH (last updated 12/17/20
Resource: COVID-19: Potency Assay Considerations for Monoclonal Antibodies and Other Therapeutic Proteins Targeting SARS-CoV-2 Infectivity
Source: U.S. Food and Drug Administration
Synopsis: The FDA
Resource: Post-acute COVID-19 Syndrome. Incidence and risk factors: a Mediterranean cohort study
Source: Journal of Infection
Synopsis: 277 PCR-confirmed COVID-19 survivors were evaluated 10-14 weeks
Resource: FDA Statement on Following the Authorized Dosing Schedules for COVID-19 Vaccines
Source: U.S. Food and Drug Administration
Synopsis: The FDA has followed discussions and news reports
Resource: Maintaining Safety with SARS-CoV-2 Vaccine
Source: New England Journal of Medicine
Synopsis: A review article, focused on immediate allergic responses to the 6 COVID-19 vaccines that are
Resource: Alert Regarding SARS-CoV-2 Viral Mutation to Health Care Providers and Clinical Laboratory Staff
Source: U.S. Food and Drug Administration
Synopsis: The FDA is alerting clinical laboratory
Resource: FDA Announcement of Coronavirus Aid and Consumer Protections
Source: U.S. Food and Drug Administration
Synopsis: The FDA posted a new webpage on the Coronavirus Aid, Relief, and Economic
Resource: South African Covid variant appears to ‘obviate’ antibody drugs, Dr. Scott Gottlieb says
Source: CNBC
Synopsis: The South African variant is also known as 501.V2, and in mid-December
Resource: COVID-19: New Coronavirus Variant is Identified in the UK
Source: British Medical Journal
Synopsis: VUI-202012/01 (the first “Variant Under Investigation” in December 2020) and is defined by